MediWound is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, we are committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
On track to initiate EscharEx ® Phase III study in fourth quarter 2023 NexoBrid ® U.S. launch expected in early third quarter 2023 Cash of over $57 million; Operating cash runway through profitability Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, May 30, 2023 (GLOBE
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time YAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its